Adam George - GW Pharmaceuticals CFO, Company Secretary, Director

<div class='circular--portrait' style='background:#FF6600;color: #f7f7f7;font-size:4em;padding-top: 25px;;'>GP</div>
GWPH -- USA Stock  

USD 132.19  4.29  3.35%

  Director
Mr. Adam David George is Chief Financial Officer, Company Secretary, Director of GW Pharmaceuticals PLC. Prior to taking on his current role, Mr. George served as our Financial Controller since 2007. Mr. George has previously occupied several senior finance roles within both public and privatelyowned companies, most recently as Finance Director from 2004 to 2007 and as Group Financial Controller from 2001 to 2004 of Believe It Group Limited, a telecommunications service provider
Age: 43  Director Since 2012      
(44) 1223 235667  www.gwpharm.com
George holds a BSc. in Biology from Bristol University and is qualified as a chartered accountant.

Adam George Latest Insider Activity

GW Pharmaceuticals Management Efficiency

GW Pharmaceuticals Plc has return on total asset (ROA) of (5.79) % which means that it has lost $5.79 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 4.88 %, meaning that it created $4.88 on every $100 dollars invested by stockholders. GW Pharmaceuticals management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current Return on Investment is estimated to decrease to -17.2. The current Return on Average Assets is estimated to decrease to -0.01GW Pharmaceuticals Revenue to Assets are most likely to slightly decrease in the upcoming years. The last year's value of Revenue to Assets was reported at 0.0101. The current Total Assets Per Share is estimated to increase to 2.01, while Total Assets are estimated to decrease to roughly 884.4 M. The current Tax Liabilities is estimated to increase to about 619.8 K, while Total Liabilities is estimated to decrease to roughly 151.2 M.
The company currently holds 40.28 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 6.37, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Michel DemareAstrazeneca PLC
2019
Tony MokAstrazeneca PLC
2019
Alan LacyBristol Myers Squibb
2008
Hans WijersGlaxoSmithKline PLC
2013
Robert BertoliniBristol Myers Squibb
2017
Nuria LapenaGrifols S A
2015
John NoseworthyMerck Company
2017
Steven MayerGrifols S A
2016
Ronald WilliamsJohnson Johnson
2011
Leslie BrunMerck Company
2016
Eugene WashingtonJohnson Johnson
2012
Nazneen RahmanAstrazeneca PLC
2017
Peter ArduiniBristol Myers Squibb
2016
Manvinder BangaGlaxoSmithKline PLC
2016
Kevin LoftonGilead Sciences
2009
Mary BeckerleJohnson Johnson
2015
Lynn ElsenhansGlaxoSmithKline PLC
2012
Marla SalmonGrifols S A
2014
Matthew EmmensBristol Myers Squibb
2017
Roy AndersonGlaxoSmithKline PLC
2007
Dinesh PaliwalBristol Myers Squibb
2013

Company Summary

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. GW Pharmaceuticals operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 901 people.GW Pharmaceuticals Plc (GWPH) is traded on BATS Exchange in USA. It is located in Sovereign House Vision Park, Chivers Way Histon, Cambridge CB24 9BZ, United Kingdom and employs 901 people. GW Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

GW Pharmaceuticals Plc Leadership Team

William Waldegrave, Non-Executive Independent Director
Christopher Tovey, COO, Executive Director
Thomas Lynch, Non-Executive Independent Director
Catherine Mackey, Non-Executive Independent Director
Justin Gover, CEO, Director
Geoffrey Guy, Executive Chairman of the Board
James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
Julian Gangolli, Executive Director
Alicia Secor, Non-Executive Independent Director
Adam George, CFO, Company Secretary, Director
Cabot Brown, Non-Executive Independent Director
Stephen Wright, Research & Development Director, Executive Director
Darren Cline, Chief Commercial Officer, U.S.

Stock Performance Indicators

Current Sentiment - GWPH

GW Pharmaceuticals Plc Investor Sentiment

Most of Macroaxis users are currently bullish on GW Pharmaceuticals Plc. What is your judgment towards investing in GW Pharmaceuticals Plc? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page